Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study
Aranow C, Allaart C, Amoura Z, Bruce I, Cagnoli P, Chatham W, Clark K, Furie R, Groark J, Urowitz M, van Vollenhoven R, Daniels M, Fox N, Gregan Y, Henderson R, van Maurik A, Ocran-Appiah J, Oldham M, Roth D, Shanahan D, Tak P, Teng Y. Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study. Annals Of The Rheumatic Diseases 2024, 83: ard-2024-225686. PMID: 39159997, PMCID: PMC11503042, DOI: 10.1136/ard-2024-225686.Peer-Reviewed Original ResearchSystemic lupus erythematosusProportion of patientsCycles of rituximabSubcutaneous belimumabLupus erythematosusSafety of sequential therapyModified intention-to-treat populationIntention-to-treat populationDisease control durationDisease controlInvestigation of combination treatmentsDisease activity markersAnti-dsDNA antibodiesDisease activity controlIntravenous placeboImmunosuppression withdrawalIntravenous rituximabSequential therapyClinical remissionStandard therapySecondary endpointsActivation markersAnti-dsDNARituximabPhase 3Disruption of memory B-cell trafficking by belimumab in patients with systemic lupus erythematosus
Arends E, Zlei M, Tipton C, Cotic J, Osmani Z, de Bie F, Kamerling S, van Maurik A, Dimelow R, Gregan Y, Fox N, Rabelink T, Roth D, Sanz I, van Dongen J, van Kooten C, Teng Y. Disruption of memory B-cell trafficking by belimumab in patients with systemic lupus erythematosus. Rheumatology 2024, 63: 2387-2398. PMID: 38775637, PMCID: PMC11371378, DOI: 10.1093/rheumatology/keae286.Peer-Reviewed Original ResearchMemory B cellsSystemic lupus erythematosusCirculating memory B cellsB cellsLupus nephritisLupus erythematosusAutoreactive memory B cellsMemory B cell subsetsSLE disease activityMemory B cell phenotypeEfficacy of belimumabSerologically active patientsHigh-sensitivity flow cytometryNaive B cellsB-cell traffickingB cell activationInhibition of B cell activationRetrospective meta-analysisBelimumab initiationIntravenous belimumabSubcutaneous belimumabBelimumabDisease activityLymphocyte traffickingAutoimmune diseases